With its treatment against eczema, Sanofi develops the biomedicament

PARIS (Reuters) – While Sanofi has been deemed late in the race for new drugs, its R & D manager believes that the expected authorization of dupilumab is opening a new era for the pharmaceutical group.

Read more here